Advertisement

SRDX

Surmodics, Inc.

Healthcare

Set alert

Price alert · SRDX

All alert types
42.98 0.00 0.00%
As of Nov 25, 2025
42.98 Day range 42.98
25.17 52-week range 42.44
YTD
+8.54%
1 year
+9.50%
Open
42.98
Prev close
42.98
Mkt cap
564.90M
Vol
5.34M
Avg vol
203.31K
EPS
-0.82
P/E
0.00
Div yield
0.00%
More statistics
Low
42.98
High
42.98
Forward P/E
141.14
Beta
1.20
Short ratio
1.62
Inst. own
84.22%
Dividend
0.00
Ex-div date
Earnings
Feb 6, 2025
50-d avg
38.89
200-d avg
37.09
1y target
43.00

2Y chart

Chart tools
Interval
SRDX two-year price chart25.229.634.138.543.0Nov 23Apr 24Sep 24Feb 25Jul 25Nov 25

Key statistics

Market cap
564.90M
Enterprise value
553.45M
Trailing P/E
0.00
Forward P/E
141.14
PEG ratio
0.00
Price / sales
4.48
Price / book
4.72
EPS (TTM)
-0.82
Beta
1.20
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-9.16%
Revenue (TTM)
126.08M
Revenue growth
18.80%
Free cash flow
7.61M
Total cash
40.11M
Total debt
29.55M
Return on equity
-9.67%
Shares outstanding
14.29M
Short % of float
3.18%
50-day average
38.89
200-day average
37.09

Analyst view

Consensus: none

Price target (mean) 43.00
Ratings (0m) 3 0 buy · 3 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold3
  • Sell0
  • Strong sell0

Next earnings

Feb 6, 2025

Expected Feb 6, 2025. Consensus EPS estimate -0.11667.

Earnings history

Financials — quick view

All financials
SRDX Revenue — quarterly 29.57M
2021-Q4 20212022-Q1 20212022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 2025
SRDX Net income — quarterly -5.32M
2021-Q4 20212022-Q1 20212022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 2025
SRDX EPS — quarterly -0.37
2021-Q4 20212022-Q1 20212022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20252025-Q3 2025

Earnings

SRDX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 6, 2025Dec 1, 2024-0.08———
Nov 6, 2024Sep 1, 2024-0.27-0.13+0.14+51.85%
Jul 31, 2024Jun 1, 2024-0.31-0.27+0.04+12.90%
May 1, 2024Mar 1, 2024-0.360.07+0.43+119.44%
Feb 1, 2024Dec 1, 2023-0.350.00——
Nov 8, 2023Sep 1, 20230.160.53+0.37+231.25%

Upgrades / downgrades

SRDX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 7, 2024Needhamreit—Hold
Aug 5, 2024Needhamreit—Hold
May 30, 2024Barrington ResearchdownOutperformMarket Perform
May 29, 2024Lake StreetdownBuyHold
May 29, 2024Sidoti & Co.downBuyNeutral
May 29, 2024NeedhamdownBuyHold

About Surmodics, Inc.

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on SRDX — it syncs with the Stock Master app.

Insider holders

SRDX insider holders
InsiderRelationLatest transactionDateShares held
ARENS TIMOTHY J.Chief Financial OfficerSaleNov 25, 202470,350
BEDOYA JOSE HDirectorStock Award(Grant)Feb 7, 202428,957
DANTZKER DAVID RDirectorStock Award(Grant)Feb 7, 202439,124
HEINE LISA WIPPERMANDirectorStock Award(Grant)Feb 7, 202413,453
KALICH RONALD B SRDirectorStock Award(Grant)Feb 7, 202438,278
KNIGHT SUSAN EDirectorStock Award(Grant)Feb 7, 202435,148

Institution ownership

SRDX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.18%1,169,67046.23MSep 29, 2024
Alliancebernstein L.P.7.28%1,040,43041.12MSep 29, 2024
Beryl Capital Management LLC6.92%988,90439.08MSep 29, 2024
Vanguard Group Inc5.62%803,50831.75MSep 29, 2024
Morgan Stanley5.27%752,70629.75MSep 29, 2024
Soleus Capital Management, L.P.4.46%637,69825.20MSep 29, 2024

Fund ownership

SRDX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.95%422,04416.68MSep 29, 2024
iShares Russell 2000 ETF2.45%350,86813.87MOct 30, 2024
Vanguard Extended Market Index Fund1.54%220,4328.71MSep 29, 2024
Fidelity Small Cap Index Fund0.98%140,6685.56MAug 30, 2024
DFA U.S. Small Cap Series0.83%118,5174.68MJul 30, 2024
Gabelli ABC Fund0.69%99,0003.91MSep 29, 2024
Advertisement